Navigation Links
VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
Date:9/18/2013

MARIETTA, Ga., Sept. 18, 2013 /PRNewswire/ -- VIVEX BIOMEDICAL, INC., a biomaterials manufacturer and developer, announced today that it has successfully completed its first round of private equity financing.  The financing involved an over-subscribed offering of the Company's preferred stock, generating $7.6 million in start-up capital. 

Tracy Anderson, President and CEO of Vivex, said, "We are grateful to our shareholders and investors.  They have provided us capital to grow our rapidly expanding biosciences portfolio while allowing the executive team to focus on the strategic execution and day to day operations.  We are excited about the future of Vivex."

Start-up capital will be used to refine current and develop new products, expand its team, and identify and pursue strategic partnerships and other opportunities.  The company's patented flagship products, currently in development, include the MIAMI stem cell and mimetic pattern implants and other protected Intellectual Property.  The company's core biomaterials include demineralized bone matrix, sponge, allograft, and calcium phosphate products backed by a proprietary cleansing process that sustains bioactivity.

About VIVEX BIOMEDICAL, INC.

Vivex commenced operations in 2013 following a spin-off of the biomaterials division of Amendia, Inc., a Marietta, Georgia spinal implant manufacturer, and has since experienced rapid growth.  In support of the biologics-oriented platform, Vivex is developing a strategic portfolio of revolutionary interactive implants that nurture and guide the body's regenerative responses for accelerated healing while minimizing recuperation. The company's soon to be released flagship products range from bioresonant mimetic implants that encourage and enhance response from the body, to a revolutionary undifferentiated adult stem cell line that retains the multi-lineage potential to repair virtually any tissue type.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal security laws.  Forward-looking statements are only predictions and are not guarantees of performance.  You should not place undue reliance on any forward-looking statements.  

For more information, please visit the company's website at www.vivex.com or contact the company's General Counsel, Michael F. Rozmajzl, Esq., CPA., at 770.575.5221.  


'/>"/>
SOURCE VIVEX BIOMEDICAL, INC.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
2. Saladax Biomedical Announces Addition to Leadership Team
3. Funding Tomorrow's Biomedical Research: California Healthcare Institute Hosts Pipeline for Life, July 15
4. The Galien Foundation Celebrates Biomedical Innovation in Fourth Galien Forum
5. David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research
6. BioMedical Life Systems, Inc. Launches New FDA Cleared Non-Prescription TENS Device
7. Ondine Biomedical CEO Carolyn Cross Appointed Treasurer of International Photodynamic Association
8. Arteriocyte announces Launch of Compass Biomedical
9. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
10. Premier Biomedical CEO Interviewed by The Wall Street Transcript
11. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
Breaking Biology Technology:
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):